Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIML NK Cells in Patients With AML or MDS
NCT01898793Phase 2Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Aug 2014
- Primary completion
- Dec 2021
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of cytokine-induced memory-like natural killer cells in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Washington University School of Medicine. Primary endpoints: Maximal Tolerated or Tested Dose at 35 days, Complete Remission Rate up to 3 years and 1 more. Started Aug 2014; status: terminated.
02
Drugs
cytokine-induced memory-like natural killer cells
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01898793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01898793.